Open an account

Adial Pharmaceuticals

ADIL · NASDAQ

$3.82+$0.20 (+5.52%)TodayMarket closed ·
Prev close $3.62

About ADIL

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Employees
5
Headquarters
Charlottesville, Virginia
Listed
Jul 27, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
adialpharma.com

ADIL key statistics

Market cap
10.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
40.23K
Volume
8.41K
Open price
$3.51
High today
$3.98
Low today
$3.51
52 Week high
$9.75
52 Week low
$1.31

Adial Pharmaceuticals (ADIL) at a glance

As of Oct 20, 2026, Adial Pharmaceuticals (ADIL) shares are priced at $3.82, giving the company a market cap of 10.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.51 and $3.98. The current price is 8.8% above the day's low and 4.0% below its high.

Volume so far is 8.41K shares, below the average of 40.23K shares a day.

Over the past year Adial Pharmaceuticals has ranged from $1.31 to $9.75, and now sits 30% of the way up that range.

Adial Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$11.25 per share against an estimate of -$1.05.

The average analyst price target is $8.50, 122.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $8.50
Low
$6.06
Now
$3.82
High
$11.55

ADIL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 29.7% on average.

  1. Q3 FY24: reported -$9.50 per share against an estimate of -$11.22
  2. Q4 FY24: reported -$8.75 per share against an estimate of -$9.69
  3. Q1 FY25: reported -$8.50 per share against an estimate of -$12.62
  4. Q2 FY25: reported -$4.50 per share against an estimate of -$6.38
  5. Q3 FY25: reported -$2.00 per share against an estimate of -$3.57
  6. Q4 FY25: reported -$3.07 per share against an estimate of -$2.19
  7. Q1 FY26: reported -$1.48 per share against an estimate of -$2.78
  8. Q2 FY26: reported -$11.25 per share against an estimate of -$1.05

ADIL news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Vandana Singh

    EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug

  • Vandana Singh

    Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

  • Vandana Singh

    EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Avi Kapoor

    Nasdaq Dips 200 Points; Alphabet Posts Upbeat Earnings

Similar companies

Companies in the same industry as Adial Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.